Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses. Issue 2 (December 2015) - Srivastava, Minu; Murriel, Christopher; Yun, Rui; Mayes, Erin; Jie, Hyun-Bae; Axelrod, Fumiko; Xie, Ming-Hong; Bentley, Trevor; Cancilla, Belinda; Tam, Raymond; O'Young, Gilbert; Kapoun, Ann; et al.